DCTH

Delcath Systems Inc

DCTH

Market cap $735K

Delisted

DCTH was delisted on the 14th of September, 2017.

Back to rankings

Healthcare Medical Instruments & Supplies

Financial journalist opinion

Delcath Systems to Participate in Upcoming Investor Conferences

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: Wells Fargo Healthcare Conference on Thursday, September 4, 2025, in Boston, MA H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, in New York, NY About Delcath Systems, Inc., HEPZATO KIT and CHE.

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating HEPZATO™ in combination with standard of care (SOC) treatment for liver-dominant metastatic colorectal cancer (mCRC). The Phase 2 trial will evaluate the safety and efficacy of HE.

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard J. Michel - CEO & Director Kevin Muir - Corporate Participant Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Bill Morgan - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

The Motley Fool

Delcath (DCTH) Q2 Revenue Jumps 210%

Delcath (DCTH) Q2 Revenue Jumps 210%

Delcath (DCTH) Q2 Revenue Jumps 210%

Zacks Investment Research

Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates

Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.48 per share a year ago.

Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT™ revenue of $22.5 million, compared to $6.6 million in.

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at The InterContinental Boston in Boston, MA. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of.

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025. The grants resulted in the right to purchase 52,500 shares of the Company's common stock and.

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Host Second Quarter 2025 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Wednesday, August 6, 20.

Delcath Systems to Host Second Quarter 2025 Earnings Call

Zacks Investment Research

Is the Options Market Predicting a Spike in Delcath Systems Stock?

Investors need to pay close attention to DCTH stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Delcath Systems Stock?

See News Rankings

Charts implemented using Lightweight Charts™